Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Open-Label, Phase II Study Comparing the Efficacy and Safety of Trastuzumab-rezetecan and Trastuzumab Deruxtecan (T-DXd) in Neoadjuvant Treatment of Patients With HER2-Positive Early or Locally Advanced Breast Cancer

NCT07416253 is registered in ClinicalTrials.gov with Henan Cancer Hospital as lead sponsor.

NCT NCT07416253
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07416253 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Open-Label, Phase II Study Comparing the Efficacy and Safety of Trastuzumab-rezetecan and Trastuzumab Deruxtecan (T-DXd) in Neoadjuvant Treatment of Patients With HER2-Positive Early or Locally Advanced Breast Cancer
Lead sponsor
Henan Cancer Hospital
Phase
Phase 2
Overall status
Not yet recruiting
Start date
March 31, 2026
Completion date
July 31, 2030
Enrollment
68 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

breast cancer